Values for preventing influenza-related morbidity and vaccine adverse events in children
- PDF / 554,205 Bytes
- 9 Pages / 610 x 792 pts Page_size
- 27 Downloads / 122 Views
Open Access
Research
Values for preventing influenza-related morbidity and vaccine adverse events in children Lisa A Prosser*1,2, Carolyn Buxton Bridges3, Timothy M Uyeki4, Virginia H Rêgo1, G Thomas Ray5, Martin I Meltzer4, Benjamin Schwartz3, William W Thompson3, Keiji Fukuda4 and Tracy A Lieu1,2,6 Address: 1Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, 133 Brookline Ave., 6th floor, Boston, MA, USA, 2Center for Child Health Care Studies, Harvard Pilgrim Health Care, Boston, MA, USA, 3National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA, 4National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA, 5Division of Research, Kaiser Permanente, Oakland, CA USA and 6Division of General Pediatrics, Children's Hospital, Boston, MA, USA Email: Lisa A Prosser* - [email protected]; Carolyn Buxton Bridges - [email protected]; Timothy M Uyeki - [email protected]; Virginia H Rêgo - [email protected]; G Thomas Ray - [email protected]; Martin I Meltzer - [email protected]; Benjamin Schwartz - [email protected]; William W Thompson - [email protected]; Keiji Fukuda - [email protected]; Tracy A Lieu - [email protected] * Corresponding author
Published: 21 March 2005 Health and Quality of Life Outcomes 2005, 3:18
doi:10.1186/1477-7525-3-18
Received: 29 November 2004 Accepted: 21 March 2005
This article is available from: http://www.hqlo.com/content/3/1/18 © 2005 Prosser et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
time-tradeoffwillingness-to-payinfluenzavaccinechildren
Abstract Background: Influenza vaccination recently has been recommended for children 6–23 months old, but is not currently recommended for routine use in non-high-risk older children. Information on disease impact, costs, benefits, risks, and community preferences could help guide decisions about which age and risk groups should be vaccinated and strategies for improving coverage. The objective of this study was to measure preferences and willingness-to-pay for changes in healthrelated quality of life associated with uncomplicated influenza and two rarely-occurring vaccinationrelated adverse events (anaphylaxis and Guillain-Barré syndrome) in children. Methods: We conducted telephone interviews with adult members selected at random from a large New England HMO (n = 112). Respondents were given descriptions of four health outcomes: uncomplicated influenza in a hypothetical 1-year-old child of their own, uncomplicated influenza in a hypothetical 14-year-old child of their own, anaphylaxis following vaccination, and Guillain-Barré syndrome. "Uncomplicated influenza" did not require a physician's visit or hospitalization. Preferences (values) for these health outcomes were measured using
Data Loading...
